SpinX Technologies seeks to apply its core competences – microfluidics, electronics, optical readout technologies, molecular biology, biochemistry and surface treatment - to the successful miniaturization of our partners' assays, rather than developing novel assays ourselves.

The SpinX platform is exquisitely suited to homogeneous assays using an optical readout, In addition, it enables miniaturized assays which use surface-bound reagents or non-optical readout modalities, including radioactive isotopes, capillary electrophoresis, and coupling to mass spectrometry.

Partnering opportunities exist for any company interested in miniaturizing their existing assays, validated in conventional formats:

Reagent and kit providers aiming to complement their offering of do-it-yourself kits with "active" kits, tightly integrated with a compact, bench-top instrument.

Fee-for-service providers aiming to improve their internal cost structure through savings on reagents and consumables while at the same time increasing the flexibility in scheduling a variety of assays.

Pharma and biotech companies aiming to eliminate manual work and reduce costs by adopting a versatile platform to perform screening assays.

Diagnostics companies aiming to develop, together with SpinX, the next generation of low-cost, single-use tools to address the needs of the emerging pharmacogenomics and molecular diagnostics markets. The consumable component – the SpinX gCard – enables minute quantities of ready-to-use reagents to be packaged onto a substrate which serves at the same time as a support to process the assay: an “active micro-package”. The powerful combination of efficient reagent packaging, integrated on-the-fly sample preparation, automated assay protocols, and the potential to integrate other micro- and nano-technologies, meets many of the needs of the emerging pharmacogenomics and molecular diagnostics markets.
contact@spinx-technologies.com